NasdaqGM - Nasdaq Real Time Price USD

Avadel Pharmaceuticals plc (AVDL)

Compare
12.69 -0.09 (-0.70%)
At close: September 25 at 4:00 PM EDT
Loading Chart for AVDL
DELL
  • Previous Close 12.78
  • Open 12.72
  • Bid 12.65 x 100
  • Ask 12.71 x 200
  • Day's Range 12.58 - 12.89
  • 52 Week Range 9.50 - 19.09
  • Volume 372,662
  • Avg. Volume 1,244,344
  • Market Cap (intraday) 1.222B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.09
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 24.60

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

www.avadel.com

154

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AVDL

View More

Performance Overview: AVDL

Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AVDL
10.13%
S&P 500
19.97%

1-Year Return

AVDL
11.90%
S&P 500
32.46%

3-Year Return

AVDL
38.69%
S&P 500
28.43%

5-Year Return

AVDL
192.40%
S&P 500
92.89%

Compare To: AVDL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AVDL

View More

Valuation Measures

Annual
As of 9/25/2024
  • Market Cap

    1.22B

  • Enterprise Value

    1.15B

  • Trailing P/E

    --

  • Forward P/E

    12.56

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.25

  • Price/Book (mrq)

    17.38

  • Enterprise Value/Revenue

    12.11

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -111.64%

  • Return on Assets (ttm)

    -34.44%

  • Return on Equity (ttm)

    -99.52%

  • Revenue (ttm)

    95.15M

  • Net Income Avi to Common (ttm)

    -106.22M

  • Diluted EPS (ttm)

    -1.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    71.38M

  • Total Debt/Equity (mrq)

    53.59%

  • Levered Free Cash Flow (ttm)

    -78.18M

Research Analysis: AVDL

View More

Company Insights: AVDL

Research Reports: AVDL

View More

People Also Watch